Sermorelin for Chronic Tendinopathy: Protocol, Dosing, and Evidence

What Is Sermorelin and Why Consider It for Tendinopathy?

Sermorelin is a synthetic analogue of the first 29 amino acids of endogenous growth hormone-releasing hormone. It binds pituitary GHRH receptors and triggers pulsatile GH secretion, which in turn drives hepatic and peripheral IGF-1 production. Tendon tissue expresses IGF-1 receptors, and IGF-1 directly stimulates tenocyte proliferation and type I collagen synthesis, two processes that stall in chronic tendinopathy.

The GH/IGF-1 Axis and Tendon Biology

Chronic tendinopathy is characterized histologically by failed healing: disorganized collagen, angiofibroblastic proliferation, and reduced tenocyte density rather than true inflammation. A 2011 review in the British Journal of Sports Medicine described this "failed healing response" and the shift from an inflammatory to a degenerative phenotype in overuse tendons, noting that anabolic signaling is attenuated in affected tissue (Maffulli N et al., Br J Sports Med, 2011).

IGF-1 is one of the central anabolic signals that tendon tissue needs for repair. Research published in the Journal of Orthopaedic Research demonstrated that IGF-1 increased collagen type I gene expression and tenocyte proliferation in vitro, supporting the mechanistic rationale for raising IGF-1 systemically through a GHRH analogue (Abrahamsson SO, J Orthop Res, 1997).

Why Sermorelin Instead of Exogenous GH?

Recombinant human GH (rhGH) raises IGF-1 more aggressively but carries a higher side-effect burden and suppresses endogenous pituitary signaling. Sermorelin preserves the normal negative-feedback loop: as GH rises, somatostatin dampens further release, keeping IGF-1 within a physiologic range. A pharmacokinetic comparison published in Endocrinology confirmed that GHRH analogues produce a GH pulse profile that mirrors natural secretion more closely than continuous rhGH infusion (Thorner MO et al., Endocrinology, 1983).

Evidence Base: What the Research Actually Shows

No randomized controlled trial has tested sermorelin specifically for chronic tendinopathy. The evidence pyramid here spans mechanistic cell studies, animal models, and observational practitioner experience. Understanding each tier prevents overstating the data.

IGF-1 and Tendon Repair: Mechanistic and Animal Data

A study in The American Journal of Sports Medicine examined IGF-1 injections directly into rat Achilles tendons and found a 35% increase in tendon cross-sectional area and improved load-to-failure mechanics at 6 weeks versus saline controls (Kurtz CA et al., Am J Sports Med, 1999). Sermorelin does not deliver IGF-1 locally; it raises circulating IGF-1. Still, this study confirms the downstream target is biologically active in tendon tissue.

A 2020 systematic review in PLOS ONE covering 22 animal studies on growth factor therapies for tendinopathy found that IGF-1 and platelet-rich plasma consistently outperformed controls on histologic scores, though the authors cautioned that translation to humans remains unproven (Boesen AP et al., Clin J Sport Med, 2017).

Growth Hormone Deficiency and Tendon Vulnerability

Adults with established GH deficiency show measurably reduced tendon stiffness. A cross-sectional study (N=40) using ultrasound elastography found that GH-deficient adults had significantly lower Achilles tendon stiffness than age-matched controls, and that 12 months of GH replacement normalized stiffness values (Colao A et al., J Clin Endocrinol Metab, 2003). This is the closest human analogue to the sermorelin hypothesis: restoring GH/IGF-1 tone improves tendon mechanical properties.

What We Cannot Yet Claim

No published trial has randomized patients with Achilles, patellar, or rotator cuff tendinopathy to sermorelin versus placebo and measured validated outcomes such as VISA-A, VISA-P, or the Western Ontario Rotator Cuff Index (WORC). Practitioners prescribing sermorelin for tendinopathy are working from mechanistic reasoning and clinical pattern recognition, not phase III data. The FDA has not approved sermorelin for this indication.

Structured Clinical Protocol for Chronic Tendinopathy

The following protocol reflects current off-label prescribing practice at integrative and sports medicine clinics. Evidence levels are labeled at each step.

Patient Selection Criteria

Candidates typically meet all of these criteria before a sermorelin trial begins:

• Confirmed tendinopathy by ultrasound or MRI (structural degeneration, not acute rupture)
• Duration of symptoms greater than 3 months despite standard care (eccentric loading, physiotherapy, NSAIDs, one or more corticosteroid or PRP injection)
• IGF-1 at or below the 50th percentile for age and sex on baseline labs
• Fasting glucose below 100 mg/dL and HbA1c below 5.7%
• No active malignancy (GH secretion is contraindicated with known or suspected cancer)
• BMI <40 kg/m² (adipose tissue impairs GH pulse amplitude)

Sermorelin is less effective in patients with significant insulin resistance because elevated insulin suppresses GH pulse amplitude. Addressing metabolic health before starting the peptide may improve outcomes (evidence level: mechanistic/observational).

Dosing and Administration

Starting dose: 200 mcg subcutaneous injection five nights per week, administered 30 to 60 minutes before sleep.

Bedtime dosing aligns the exogenous GHRH pulse with the body's largest endogenous GH secretory event, which occurs during slow-wave sleep. A study in Sleep confirmed that GH secretion is tightly coupled to sleep onset and that the first non-REM cycle produces the largest pulse of the 24-hour period (Van Cauter E et al., Sleep, 2000).

Dose titration: At week 8, if IGF-1 has not risen to the age-adjusted midrange (roughly 150 to 250 ng/mL for adults aged 30 to 60), the dose may increase to 300 mcg nightly. A further increase to 500 mcg at week 16 is reasonable if IGF-1 remains suboptimal and the patient tolerates the lower dose without adverse effects.

Maximum dose in this protocol: 500 mcg nightly. Doses above 500 mcg have not demonstrated additional IGF-1 gains in most adults and increase injection-site irritation.

Reconstitution: Bacteriostatic water (typically 2 to 5 mL per vial) is standard. Store reconstituted sermorelin refrigerated at 2 to 8 degrees Celsius and use within 30 days.

Cycle Length and Rest Periods

Tendon remodeling operates on a slow timeline. Collagen turnover in load-bearing tendons has a half-life of approximately 50 to 100 days based on stable isotope studies (Miller BF et al., Am J Physiol Endocrinol Metab, 2005). A minimum 12-week cycle is needed to capture even one full cycle of collagen turnover; 16 to 24 weeks is preferred for recalcitrant cases.

After the active phase, a 4 to 8-week rest period is recommended to allow pituitary receptor sensitivity to reset. The five-days-on, two-days-off weekly schedule (weekends off) accomplishes a mini-rest each week and may preserve pituitary responsiveness over long cycles.

Companion Eccentric Loading Program

Sermorelin provides the anabolic signal; mechanical load directs where new collagen is laid down. Without a structured loading program, systemic IGF-1 elevation does not preferentially deposit collagen in the injured tendon.

For Achilles tendinopathy, the Alfredson heavy-load eccentric protocol (3 sets of 15 repetitions twice daily, progressing to weighted decline eccentric squats) has the strongest evidence base. A landmark RCT (N=44) published in the American Journal of Sports Medicine showed 82% of patients returned to previous activity level after 12 weeks of Alfredson eccentric training versus 36% with a concentric program (Alfredson H et al., Am J Sports Med, 1998).

For patellar tendinopathy, heavy slow resistance training (HSRT, 4 sets of 6 repetitions at 85% 1RM) is preferred based on a 2015 RCT in the British Journal of Sports Medicine (N=29) showing comparable pain reduction to eccentric training at 12 weeks with better tendon structure on ultrasound (Beyer R et al., Br J Sports Med, 2015).

For rotator cuff tendinopathy, a progressive scapular and rotator cuff strengthening program three days per week is standard adjunct care, following the American Academy of Orthopaedic Surgeons clinical practice guideline (AAOS Rotator Cuff CPG, 2019).

Monitoring Labs and Safety Parameters

The following monitoring schedule represents the HealthRX clinical framework for sermorelin use in tendinopathy, synthesized from endocrine prescribing conventions and sports medicine practice patterns.

Baseline Labs (Before First Injection)

| Lab | Purpose | |---|---| | Serum IGF-1 (with age/sex reference range) | Establish baseline and guide dose titration | | Fasting glucose and HbA1c | Screen for insulin resistance; contraindication if poorly controlled | | Fasting insulin | Assess GH pulse suppression risk | | Comprehensive metabolic panel | Hepatic and renal safety screen | | Thyroid panel (TSH, free T4) | Hypothyroidism blunts GH response | | Testosterone (men) / estradiol (women) | Sex hormone milieu affects IGF-1 | | PSA (men over 40) | Baseline before any anabolic protocol | | CBC | General health screen |

On-Treatment Labs

• Week 8: IGF-1, fasting glucose, HbA1c. Adjust dose if IGF-1 remains below the midrange.
• Week 16: Full repeat of baseline panel. Confirm IGF-1 is within the age-adjusted reference range, not above the upper limit.
• Week 24 (end of cycle): Full panel plus musculoskeletal ultrasound of the affected tendon to document structural change.

Target IGF-1 during treatment: 150 to 250 ng/mL for adults aged 30 to 60. Levels above 300 ng/mL should prompt dose reduction. Chronically supraphysiologic IGF-1 is associated with acromegalic changes and may increase cancer risk, though the risk at sermorelin-achievable IGF-1 levels appears low based on pharmacokinetic data (Freda PU et al., J Clin Endocrinol Metab, 2009).

Common Side Effects and Management

Injection-site reactions: Redness and mild swelling resolve within 24 to 48 hours in most patients. Rotating injection sites (abdomen left, abdomen right, thigh left, thigh right) reduces cumulative irritation.

Transient water retention: Mild edema in the first 2 to 4 weeks is common as IGF-1 promotes sodium reabsorption. Spontaneous resolution is typical; reducing dietary sodium to below 2,300 mg/day accelerates resolution.

Carpal tunnel symptoms: Tingling in the hands may indicate early fluid accumulation. Dose reduction by 50 mcg usually resolves this within one week.

Headache: Typically mild and self-limiting in the first two weeks. Persistent headache warrants intracranial pressure evaluation.

Expected Timeline of Outcomes

Tendon remodeling is slow. Setting realistic expectations prevents premature discontinuation.

Weeks 1 to 4

Most patients report no structural change. Sleep quality often improves because GH pulses deepen slow-wave sleep. Some report reduced stiffness in the morning, which may reflect reduced systemic inflammation rather than tendon repair.

Weeks 4 to 12

IGF-1 reaches a new steady-state by week 4 to 6 if dosing is consistent. Tenocyte activity should be increasing during this window. Pain scores on validated tools (VISA-A for Achilles, VISA-P for patellar) may begin declining by weeks 8 to 12 if loading is concurrent. A reduction of 10 to 15 points on the VISA-A (scale 0 to 100, lower is worse) is a clinically meaningful change based on the minimal detectable change data from the original VISA-A validation (Robinson JM et al., Br J Sports Med, 2001).

Weeks 12 to 24

Ultrasound may show reduced hypoechogenicity (a marker of degeneration) and improved tendon homogeneity by week 16 to 24 if the protocol is followed consistently. Full functional recovery varies by tendon location, severity, and patient age.

Older adults (over 50) may need the full 24-week cycle. Tendon collagen synthesis rates decline with age, and GH pulse amplitude is naturally lower, meaning sermorelin's effect size is smaller than in younger patients (Welle S et al., J Clin Endocrinol Metab, 1996).

Combining Sermorelin with Other Tendinopathy Interventions

PRP and Sermorelin

Platelet-rich plasma (PRP) delivers concentrated growth factors locally. A 2022 meta-analysis in the British Journal of Sports Medicine (14 RCTs, N=1,066) found that leukocyte-poor PRP produced a statistically significant improvement in VISA-A scores at 6 months versus saline for Achilles tendinopathy (mean difference: 12.7 points, P<0.001) (Fitzpatrick J et al., Br J Sports Med, 2017). Sermorelin and PRP are not mutually exclusive; PRP addresses local growth factor delivery while sermorelin raises the systemic anabolic tone.

Collagen Peptide Supplementation

Fifteen grams of hydrolyzed collagen consumed 60 minutes before loading exercise may increase collagen synthesis in tendons based on a 2017 study in the American Journal of Clinical Nutrition (N=8, crossover design) showing a doubling of serum prolyl-hydroxyproline and a significant increase in collagen synthesis markers (Shaw G et al., Am J Clin Nutr, 2017). This is a low-risk adjunct that may potentiate the anabolic environment sermorelin creates.

Shockwave Therapy

Extracorporeal shockwave therapy (ESWT) is guideline-supported for calcific rotator cuff tendinopathy and refractory Achilles tendinopathy. The American Academy of Orthopaedic Surgeons recommends considering ESWT for calcific tendinitis of the shoulder after failed conservative care (AAOS CPG, 2019). ESWT stimulates local angiogenesis and tenocyte activity and may act synergistically with the elevated IGF-1 environment that sermorelin provides.

Regulatory and Compounding Considerations

Sermorelin is available in the United States as a compounded preparation from 503A and 503B pharmacies. The FDA approved sermorelin acetate (Geref) for pediatric GH deficiency in 1990, and the original brand was withdrawn from the market in 2008 (FDA drug database, NDA 019760). Adult and tendinopathy use relies entirely on compounded formulations prescribed off-label by licensed physicians.

The FDA's 2023 guidance on compounded peptides raised questions about the status of several growth hormone secretagogues. Prescribers should confirm current compounding status with their pharmacy and document the medical necessity rationale in the patient's chart. The Endocrine Society's clinical practice guideline on adult GH deficiency does not specifically address sermorelin for tendinopathy, but it provides dosing frameworks for GH replacement that inform safe IGF-1 target ranges (Molitch ME et al., J Clin Endocrinol Metab, 2011).